Titlebook: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response; Federico Innocenti Book 2009 Humana Press 2009 DNA.Dro

Expiration

https://doi.org/10.1007/978-1-60327-088-5DNA; Drogen; MicroRNAs; Microarrays; Oncology drug development; Pharmacogenomics; Single Nucleotide Polymo

indecipherable

Federico InnocentiComprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry.Provides a collection of multi-disciplinary topics.Covers the most impor

brother

https://doi.org/10.1007/978-3-658-24393-7tial, however, there have been few breakthroughs that can be directly attributed to microarray-based profiling. While many researchers now say that microarrays have been over-hyped, it is more likely that early experiments were simply conducted in a na?ve manner. Many believe that as technology and

合并

免費(fèi)

Baffle

Larry A. Magliocca,Karen E. Sandersslated region of target messenger RNAs. At present, hundreds of microRNAs have been identified in humans, and some of them have been revealed to play a critical role especially in the initiation, progression, and malignant potential of various cancers. In this chapter, we discuss the role of microRN

食物

degradation

討好美人

Dialogues Between Physics and Mathematicsselection. However, the cancer genome is altered by many processes that could affect the expression of functional alleles in the tumor. Consequently the utility of the germline genome to predict the tumor genome is under question. Studies have suggested strong concordance between the germline and tu

Clinch

Part I. Beyond the Doubt of a Shadowtypical member of the ErbB family of RTKs, which can form homodimers or heterodimers with other ErbB family members upon ligation with a variety of EGF-related extracellular ligands to facilitate transphosphorylation and downstream signaling..EGFR, as well as other ErbB family members and their cogn